Arendt advised CD&R on the Luxembourg legal aspects of the partnership with Sanofi to acquire Opella

Experts involved in the Deal

Arendt advised Clayton Dubilier & Rice (CD&R) on the Luxembourg legal aspects of the acquisition by CD&R of a 50% controlling stake of the Sanofi’s consumer healthcare business Opella for approximately 10 billion euros. Sanofi remains a significant shareholder with a 48.2% stake and the French State through Bpifrance owns a 1.8% stake.

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 strategic manufacturing sites and 4 science and innovation development centers. With a portfolio of iconic brands, such as Allegra, Doliprane, and Dulcolax, Opella is already the third-largest business worldwide in the over-the-counter and vitamins, minerals & supplements market (OTC & VMS), serving more than half a billion consumers worldwide.

CD&R has a strong history of collaborating with corporate teams and management to foster business growth and development. The firm leverages its global presence, deep industry knowledge, and extensive network of operating partners and advisors. With over twenty years of experience in Europe, CD&R has a proven track record in building leading French companies and supporting French employment.